A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia
A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia
微粉化白藜芦醇治疗弗里德赖希共济失调的随机安慰剂对照交叉试验
批准号：
nhmrc : 1102207
负责人：
A/Pr John O'Sullivan
金额：
$37.33万
依托单位国家：
澳大利亚
项目类别：
Project Grants
财政年份：
2016
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2016-01-01 至 2020-12-31
中文摘要
翻译
Friedreich共济失调(FRDA)是导致共济失调(不协调)的最常见的遗传原因。目前还没有被证明可以减缓或逆转其不可阻挡的进展的治疗方法。我们已经在一项开放标签研究中证明了白藜芦醇作为一种治疗方法的前景，现在提出了一项安慰剂对照研究，将提供白藜芦醇是否可以减缓或逆转这种破坏性疾病的症状的证据。
英文摘要
Friedreich ataxia (FRDA) is the most common inherited cause of ataxia (incoordination). There are currently no treatments proven to slow or reverse its inexorable progression. We have shown that resveratrol holds promise as a treatment in an open-label study and now propose a placebo controlled study that will provide evidence of whether resveratrol can slow or reverse symptoms in this devastating disorder.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia
-
批准号：nhmrc : GNT1102207
-
项目类别：Project Grants
-
资助金额：$55.63万
-
财政年份：2016
-
负责人：A/Pr John O'Sullivan
-
依托单位：
Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
-
批准号：nhmrc : 1082250
-
项目类别：Project Grants
-
资助金额：$33.2万
-
财政年份：2015
-
负责人：A/Pr John O'Sullivan
-
依托单位：
Therapeutic Targeting of Complement C5a Receptors in HuntingtonÍs Disease
-
批准号：nhmrc : 1004455
-
项目类别：Project Grants
-
资助金额：$31.23万
-
财政年份：2011
-
负责人：A/Pr John O'Sullivan
-
依托单位：
海外基金
